For the first quarter 2013, we project total sales of $505 million to $530 million and diluted earnings per share, excluding the $0.07 benefit from the 2012 R&D tax credit and any other special items, between $0.74 and $0.78.About Edwards LifesciencesEdwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring.